Integrase inhibitor MK-0518: Merck opens expanded-access program.
Patients resistant to at least one drug in all three oral classes may qualify for this new kind of antiretroviral--which still must be combined with other active drugs.
James
John S
JS
D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000600:supply & distribution / Q000627:therapeutic use*; D006801:Humans; D009930:Organic Chemicals / Q000600:supply & distribution / Q000627:therapeutic use*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
D019428:HIV Integrase Inhibitors; D009930:Organic Chemicals; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium